Arthritis & Rheumatology · 2018 · 97 citations · 46 references
Life SciencesImmunologyPharmacotherapyClinical ImmunologyImmunotherapyRheumatologyAutoimmune DiseasesImmune-mediated Inflammatory DiseasesImmunotherapy SafetyInflammatory ArthritisInflammatory Disease PharmacotherapyPsoriatic ArthritisDisease Activity MeasurementDisease Severity IndexDual Variable Domain ImmunoglobulinsInterleukin-17 InhibitorsPrimary Efficacy EndpointsPsoriasis TherapyPsoriatic DiseaseTumor Necrosis Factor Therapy
OBJECTIVE: To investigate the safety and efficacy of ABT-122, a tumor necrosis factor (TNF)- and interleukin-17A (IL-17A)-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate. METHODS: Patients (n = 240) were randomized to receive ABT-122 (120 or 240 mg every week), adalimumab (40 mg every other week), or placebo in a 12-week double-blind, parallel-group study. The primary efficacy end point was the proportion of patients achieving ≥20% improvement in disease activity according to the American College of Rheumatology response criteria (ACR20) at week 12. Secondary and exploratory 12-week end points included 50% improvement (ACR50) and 70% improvement (ACR70) response rates, and proportion of patients meeting the Psoriasis Area and Severity Index (PASI) response criteria for ≥75% (PASI75) and ≥90% (PASI90) improvement in skin scores among those with ≥3% of their body surface area affected by psoriasis. RESULTS: In both ABT-122 dose groups, ACR20 response rates at week 12 (64.8-75.3%) were superior to that in patients receiving placebo (25.0%) (P < 0.001) but similar to that in patients receiving adalimumab (68.1%). ACR50 and ACR70 response rates were also superior in both ABT-122 dose groups (36.6-53.4% and 22.5-31.5%, respectively) compared to the placebo group (12.5% and 4.2%, respectively) (P < 0.05). Among eligible patients in the placebo, adalimumab, ABT-122 120 mg every week, and ABT-122 240 mg every week treatment groups, PASI75 responses were achieved in 27.3%, 57.6%, 74.4%, and 77.6% of patients, respectively, whereas PASI90 responses were achieved in 18.2%, 45.5%, 48.8%, and 46.9% of patients, respectively. Frequencies of treatment-emergent adverse events, including infections, were similar across all treatment groups, causing no discontinuations. No serious infections or systemic hypersensitivity reactions were reported with ABT-122. CONCLUSION: Dual neutralization of TNF and IL-17A with ABT-122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12-week treatment course in patients with PsA.
46
M.L.L. Prevoo, Martin A. van't Hof, H. H. Kuper et al. · Arthritis & Rheumatism · 1995 · 6.2K citations
Severe Psoriasis – Oral Therapy with a New Retinoid
T Fredriksson, U. Pettersson · Dermatologica · 2009 · 2.7K citations
Medicine, Dermatology, Pharmacology +11
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Dermatology, Immunology +14